Insider Trading Activity Atara Biotherapeutics Inc (NASDAQ:ATRA) – CEO Sold 4,800 shares of Stock

11

Insider Trading Activity For Atara Biotherapeutics Inc (NASDAQ:ATRA)

Isaac E Ciechanover , CEO of Atara Biotherapeutics Inc (NASDAQ:ATRA) reportedly Sold 4,800 shares of the company’s stock at an average price of 14.91 for a total transaction amount of $71,568.00 SEC Form

Insider Trading History For Atara Biotherapeutics Inc (NASDAQ:ATRA)

  • On 10/21/2014 Domain Partners Viii, L.P., Major Shareholder, bought 248,159 with an average share price of $11.00 per share and the total transaction amounting to $2,729,749.00. View SEC Filing
  • On 2/18/2015 Carol Giltner Gallagher, Director, bought 11,000 with an average share price of $18.00 per share and the total transaction amounting to $198,000.00. View SEC Filing
  • On 3/10/2015 Joel S Marcus, Director, bought 4,000 with an average share price of $29.57 per share and the total transaction amounting to $118,280.00. View SEC Filing
  • On 4/23/2015 Isaac E Ciechanover, CEO, sold 5,200 with an average share price of $61.36 per share and the total transaction amounting to $319,072.00. View SEC Filing
  • On 5/22/2015 Isaac E Ciechanover, CEO, sold 4,000 with an average share price of $37.56 per share and the total transaction amounting to $150,240.00. View SEC Filing
  • On 5/29/2015 John Mcgrath, CFO, sold 10,000 with an average share price of $40.00 per share and the total transaction amounting to $400,000.00. View SEC Filing
  • On 6/1/2015 Christopher Haqq, Insider, sold 2,500 with an average share price of $41.47 per share and the total transaction amounting to $103,675.00. View SEC Filing
  • Analyst Ratings For Atara Biotherapeutics Inc (NASDAQ:ATRA)
    These are 2 Sell Ratings, 3 Buy Ratings .
    The current consensus rating for Atara Biotherapeutics Inc (NASDAQ:ATRA) is Hold (Score: 2.20) with a consensus target price of $24.00 , a potential (58.42% upside)

    Analyst Ratings History For Atara Biotherapeutics Inc (NASDAQ:ATRA)

    • On 12/15/2015 William Blair Reiterated Rating Buy
    • On 3/9/2016 JPMorgan Chase & Co. Lower Price Target of rating Market Outperform with a price target of $40.00 to $34.00
    • On 7/9/2016 JMP Securities Reiterated Rating Buy
    • On 9/15/2016 Goldman Sachs Group Inc Downgraded rating Neutral to Sell with a price target of $23.00 to $16.00
    • On 12/12/2016 Jefferies Group LLC Set Price Target of rating Buy with a price target of $23.00
    • On 3/16/2017 Citigroup Inc Set Price Target of rating Sell with a price target of $10.00
    • On 4/21/2017 Canaccord Genuity Reiterated Rating Buy with a price target of $47.00

    About Atara Biotherapeutics Inc (NASDAQ:ATRA)
    Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company’s product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company’s T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

    Recent Trading Activity for Atara Biotherapeutics Inc (NASDAQ:ATRA)
    Shares of Atara Biotherapeutics Inc closed the previous trading session at 15.15 up +0.05 0.33% with 164,841 shares trading hands.

    An ad to help with our costs